Abstract
Cardiac resynchronization therapy (CRT) is a disease modifying, device-driven treatment that can reduce morbidity and mortality in patients with heart failure. According to the current guidelines, the indication for CRT is only based on QRS duration and functional class of heart failure. However, a substantial amount of patients do not respond to therapy. In addition, CRT is accompanied by significant cost and potential morbidity. It is therefore vital to improve patient selection for CRT to improve patient outcome and minimize therapy-related complications. In this regard, cardiac sympathetic innervation may be of interest. This review addresses the currently available literature, 9 studies with a total number of 225 patients, on CRT and cardiac innervation scintigraphy with 123I-metaiodobenzylguanidine.
Similar content being viewed by others
References
Authors/Task Force Members, Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C et al (2010) 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the heart failure association and the European heart rhythm association. Eur Heart J 31:2677–2687
Pires LA, Abraham WT, Young JB, Johnson KM (2006) Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the multicenter InSync randomized clinical evaluation (MIRACLE) and multicenter InSync ICD randomized clinical evaluation (MIRACLE-ICD) trials. Am Heart J 151:837–843
Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA et al (2010) Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol 55:2212–2221
Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H et al (2007) Guidelines for cardiac pacing and cardiac resynchronization therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European society of cardiology. Developed in collaboration with the European heart rhythm association. Eur Heart J 28:2256–2295
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European society of intensive care medicine (ESICM). Eur J Heart Fail 10:933–989
Erol-Yilmaz A, Verberne HJ, Schrama TA, Hrudova J, De Winter RJ, Van Eck-Smit BL et al (2005) Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 28:304–310
Higuchi K, Toyama T, Tada H, Naito S, Ohshima S, Kurabayashi M (2006) Usefulness of biventricular pacing to improve cardiac symptoms, exercise capacity and sympathetic nerve activity in patients with moderate to severe chronic heart failure. Circ J 70:703–709
Gould PA, Kong G, Kalff V, Duffy SJ, Taylor AJ, Kelly MJ et al (2007) Improvement in cardiac adrenergic function post biventricular pacing for heart failure. Europace 9:751–756
Nishioka SA, Martinelli Filho M, Brandao SC, Giorgi MC, Vieira ML, Costa R et al (2007) Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol 14:852–859
Burri H, Sunthorn H, Somsen A, Fleury E, Stettler C, Shah D et al (2008) Improvement in cardiac sympathetic nerve activity in responders to resynchronization therapy. Europace 10:374–378
Cha YM, Oh J, Miyazaki C, Hayes DL, Rea RF, Shen WK et al (2008) Cardiac resynchronization therapy upregulates cardiac autonomic control. J Cardiovasc Electrophysiol 19:1045–1052
Cha YM, Chareonthaitawee P, Dong YX, Kemp BJ, Oh JK, Miyazaki C et al (2011) Cardiac sympathetic reserve and response to cardiac resynchronization therapy. Circ Heart Fail 4:339–344
Shinohara T, Takahashi N, Saito S, Okada N, Wakisaka O, Yufu K et al (2011) Effect of cardiac resynchronization therapy on cardiac sympathetic nervous dysfunction and serum C-reactive protein level. Pacing Clin Electrophysiol 34:1225–1230
Tanaka H, Tatsumi K, Fujiwara S, Tsuji T, Kaneko A, Ryo K et al (2012) Effect of left ventricular dyssynchrony on cardiac sympathetic activity in heart failure patients with wide QRS duration. Circ J 76:382–389
Xu YZ, Cha YM, Feng D, Powell BD, Wiste HJ, Hua W et al (2012) Impact of myocardial scarring on outcomes of cardiac resynchronization therapy: extent or location? J Nucl Med 53:47–54
Adelstein EC, Tanaka H, Soman P, Miske G, Haberman SC, Saba SF et al (2011) Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J 32:93–103
D’Andrea A, Caso P, Scarafile R, Riegler L, Salerno G, Castaldo F et al (2009) Effects of global longitudinal strain and total scar burden on response to cardiac resynchronization therapy in patients with ischaemic dilated cardiomyopathy. Eur J Heart Fail 11:58–67
Kandala J, Altman R, Park M, Singh J (2012) Clinical, laboratory, and pacing predictors of CRT response. J Cardiovasc Transl Res 5:196–212. doi:10.1007/s12265-012-9352-0
Bleeker GB, Bax JJ, Fung JW, van der Wall EE, Zhang Q, Schalij MJ et al (2006) Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol 97:260–263
Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schafers M et al (2010) Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM cardiovascular committee and the European council of nuclear cardiology. Eur J Nucl Med Mol Imaging 37:1802–1812
Dobbeleir AA, Hambye AS, Franken PR (1999) Influence of high-energy photons on the spectrum of iodine-123 with low- and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice. Eur J Nucl Med 26:655–658
Inoue Y, Suzuki A, Shirouzu I, Machida T, Yoshizawa Y, Akita F et al (2003) Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake. J Nucl Cardiol 10:623–632
Verberne HJ, Feenstra C, de Jong W, Somsen G, Eck-Smit B, Busemann Sokole E (2005) Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging 32:1100–1710
Acknowledgments
The work was performed at the University Medical Center Utrecht, The Netherlands.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scholtens, A.M., Braat, A.J.A.T., Tuinenburg, A. et al. Cardiac sympathetic innervation and cardiac resynchronization therapy. Heart Fail Rev 19, 567–573 (2014). https://doi.org/10.1007/s10741-013-9400-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-013-9400-0